Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses the FDA approval of atezolizumab (Tecentriq) for the treatment of patients with non—small cell lung cancer (NSCLC).

The approval is based on multiple clinical trials, the largest being the phase III OAK trial, which was presented at the 2016 ESMO Congress. In the study, atezolizumab reduced the risk of death by 26% compared with docetaxel in patients with advanced NSCLC following the failure of platinum-based chemotherapy. The median overall survival was improved by 4.2 months with the PD-L1 inhibitor versus chemotherapy. The survival benefit with atezolizumab was observed regardless of PD-L1 status or histology.

Videos

Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses the FDA approval of atezolizumab (Tecentriq) for the treatment of patients with non–small cell lung cancer (NSCLC).

Sangeetha Palakurthi on FDA Approval of Atezolizumab in NSCLC

Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses a study that utilized non—small cell lung cancer (NSCLC) patient-derived xenografts (PDXs) from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies.

Researchers have conducted clinical trials looking at biomarker efficacy and combination regimens to better understand patient resistance to osimertinib, Palakurthi explains. This is to help gain a greater understanding of the appropriate treatments for these patients, or to possibly extend durations of response in patients with short-term responses to osimertinib.

Therefore, a platform of NSCLC PDXs was developed in order to refine treatment strategies in these patients, Palakurthi adds.

Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses a study that utilized nonâ€“small cell lung cancer (NSCLC) patient-derived xenografts from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies.


Sangeetha Palakurthi, PhD

Articles

Sangeetha Palakurthi on FDA Approval of Atezolizumab in NSCLC

Sangeetha Palakurthi on Strategies for Managing Resistance to Osimertinib in Patients With NSCLC